S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
U.S. Loses to China in Shocking WAR GAMES (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
U.S. Loses to China in Shocking WAR GAMES (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
U.S. Loses to China in Shocking WAR GAMES (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
U.S. Loses to China in Shocking WAR GAMES (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
U.S. Loses to China in Shocking WAR GAMES (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
U.S. Loses to China in Shocking WAR GAMES (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
U.S. Loses to China in Shocking WAR GAMES (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
U.S. Loses to China in Shocking WAR GAMES (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
NASDAQ:MRNS

Marinus Pharmaceuticals (MRNS) Stock Forecast, Price & News

$8.05
-0.19 (-2.31%)
(As of 09/29/2023 ET)
Compare
Today's Range
$7.65
$8.28
50-Day Range
$5.86
$10.89
52-Week Range
$3.46
$11.15
Volume
1.07 million shs
Average Volume
825,944 shs
Market Capitalization
$407.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.50

Marinus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
167.1% Upside
$21.50 Price Target
Short Interest
Bearish
7.49% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.56
Upright™ Environmental Score
News Sentiment
0.59mentions of Marinus Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$131,258 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.56) to ($2.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

181st out of 970 stocks

Pharmaceutical Preparations Industry

65th out of 450 stocks


MRNS stock logo

About Marinus Pharmaceuticals (NASDAQ:MRNS) Stock

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

MRNS Price History

MRNS Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Marinus Pharmaceuticals (NASDAQ:MRNS) PT Raised to $21.00
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Marinus (MRNS) Receives a Buy from JMP Securities
H.C. Wainwright Sticks to Their Buy Rating for Marinus (MRNS)
See More Headlines
Receive MRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MRNS Company Calendar

Last Earnings
8/10/2023
Today
9/30/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRNS
Employees
151
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.50
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+167.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-19,820,000.00
Net Margins
-113.01%
Pretax Margin
-99.51%

Debt

Sales & Book Value

Annual Sales
$25.48 million
Book Value
$2.26 per share

Miscellaneous

Free Float
48,150,000
Market Cap
$407.41 million
Optionable
Optionable
Beta
1.35
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Scott N. Braunstein M.D. (Age 60)
    CEO, Pres & Chairman
    Comp: $919.29k
  • Mr. Steven E. Pfanstiel C.M.A. (Age 49)
    M.B.A., COO, CFO & Treasurer
    Comp: $580.35k
  • Dr. Joseph Hulihan M.D. (Age 67)
    Chief Medical Officer
    Comp: $639.51k
  • Dr. Alex Aimetti Ph.D.
    Chief Scientific Officer
  • Ms. Sonya Weigle
    Sr. VP of Investor Relations, HR & Corp. Affairs
  • Ms. Martha E. Manning Esq. (Age 68)
    J. D., Sr. VP, Gen. Counsel & Sec.
  • Molly Cameron
    Director of Corp. Communications & Investor Relations
  • Dr. Kimberly A. McCormick Pharm.D.
    PharmD, Chief Regulatory & Quality Assurance Officer
  • Mr. Thomas J. Lyons
    Chief Bus. Officer
  • Ms. Christina Shafer (Age 47)
    Chief Commercial Officer













MRNS Stock - Frequently Asked Questions

Should I buy or sell Marinus Pharmaceuticals stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRNS shares.
View MRNS analyst ratings
or view top-rated stocks.

What is Marinus Pharmaceuticals' stock price forecast for 2023?

9 brokerages have issued 12 month target prices for Marinus Pharmaceuticals' stock. Their MRNS share price forecasts range from $9.00 to $32.00. On average, they predict the company's share price to reach $21.50 in the next year. This suggests a possible upside of 167.1% from the stock's current price.
View analysts price targets for MRNS
or view top-rated stocks among Wall Street analysts.

How have MRNS shares performed in 2023?

Marinus Pharmaceuticals' stock was trading at $3.98 on January 1st, 2023. Since then, MRNS stock has increased by 102.3% and is now trading at $8.05.
View the best growth stocks for 2023 here
.

When is Marinus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our MRNS earnings forecast
.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) issued its quarterly earnings results on Thursday, August, 10th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.15. The biopharmaceutical company earned $6.08 million during the quarter, compared to the consensus estimate of $5.14 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 139.10% and a negative net margin of 113.01%.

What ETFs hold Marinus Pharmaceuticals' stock?

ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) and iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

When did Marinus Pharmaceuticals' stock split?

Shares of Marinus Pharmaceuticals reverse split on the morning of Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Marinus Pharmaceuticals own?
What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $8.05.

How much money does Marinus Pharmaceuticals make?

Marinus Pharmaceuticals (NASDAQ:MRNS) has a market capitalization of $407.41 million and generates $25.48 million in revenue each year. The biopharmaceutical company earns $-19,820,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.

How many employees does Marinus Pharmaceuticals have?

The company employs 151 workers across the globe.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The official website for the company is www.marinuspharma.com. The biopharmaceutical company can be reached via phone at (484) 801-4670, via email at lcaperelli@marinuspharma.com, or via fax at 203-315-0565.

This page (NASDAQ:MRNS) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -